Abstract Patients with osteogenesis imperfecta (OI) show various degrees of bone fragility. Nevertheless, details of the mechanisms causing bone fragility remain unclear. We hypothesized that differences in pyridinoline cross-link formation at the N-and C-termini in type I collagen molecules partly contribute to bone fragility of OI. To verify this hypothesis, urinary N and C terminal telopeptides of type I collagen (uNTx and uβCTx, respectively) and urinary hydroxyproline (uHyp) were measured using second morning void urine samples obtained from OI patients and healthy control children. Ratios of uNTx and uβCTx to uHyp (uNTx/uHyp and uβCTx/uHyp, respectively) of OI patients and healthy normal control children were analyzed. Ratios of uNTx to uβCTx (uNTx/uβCTx) were also analyzed. In OI patients, uNTx and uβCTx were lower than in healthy control children. Also, uNTx/uHyp and uβCTx/ uHyp were signifi cantly lower than in healthy children. Among OI patients, uNTx/uHyp and uNTx/uβCTx of type III OI were signifi cantly lower than of either type I or type IV OI. These results show that pyridinoline cross-link formation is lower than in healthy control children and that pyridinoline cross-link formation at the N-and C-termini in type I collagen molecules might be differently disrupted in OI patients according to the severity of OI.
Introduction
Osteogenesis imperfecta (OI) is a heritable bone disorder caused by defects of a type I collagen (Col I) gene: COL1A1 and COL1A2, respectively, encode α1 (I) chain and α2 (I) chain. Sillence classifi ed OI into four groups according to their modes of inheritance and their clinical manifestation in 1979 [1] . Recently, type V [2] , type VI [3] , and type VII [4] are newly classifi ed from type IV, which shows no mutation of the Col I gene [5] .
The clinical hallmark of OI is bone fragility. Bone fragility in OI shows a broad spectrum of outcomes, from perinatal lethality to lack of clinical symptoms. Although factors related to bone fragility such as bone mineral density [6] , bone turnover markers [7] [8] [9] , and genetic mutation of Col I gene have been studied [10] [11] [12] , the mechanism that causes various degrees of bone fragility in OI patients remains unclear. We hypothesize that a genetic mutation of Col I gene affects the formation of pyridinoline cross-links that form at N-and C-termini of Col I molecules and connect Col I molecules tightly, and that different pyridinoline cross-link formation contributes to various degrees of bone fragility in patients with OI. To verify these hypotheses, we evaluated the pyridinoline cross-link formation at N-and C-termini independently in OI patients and healthy control patients by measuring urinary N-and C-terminal telopeptides of type I collagen [13] , which derive from pyridinoline cross-links between Col I molecules.
Materials and methods

Patients with osteogenesis imperfecta and healthy control children
This study examined 20 prepubertal Japanese patients with osteogenesis imperfecta (OI) who were observed at our hospital or at a related institution from 2003 to 2005, along with age-and sex-matched healthy Japanese children. Based on Sillence's classifi cation system [1] , the OI patients were classifi ed into three groups (type I, type III, type IV). Type II OI patients were not involved in this study. The OI patients' background is shown in Table 1 .
All OI patients were free from pamidronate treatment for at least 3 months, except four patients had not yet received their fi rst pamidronate infusion [type I, 3 (5-monthold and 27-month-old male patients and an 11-month-old female patient); type III, 1 (12-month-old female patient]. All OI patients had been free of bone fractures for at least 3 months. No OI patients had impaired renal function. Informed consent was obtained from legal guardians of OI patients and healthy control children before collecting the blood and urine samples. This study was approved by the ethical committee of each institution.
Measurement of urinary bone degenerative markers
Second morning void urine samples were collected from OI patients and age-and sex-matched control children. Urinary excretion of N-terminal telopeptides of type I collagen (uNTx) and C terminal telopeptides of type I collagen (uβCTx) were measured, respectively, at Mitsubishi Kagaku Bio-Clinical Laboratories (MBC) using an enzyme-linked immunosorbent assay (ELISA) using Osteomark NTx (Wampole; Inverness Medical Innovations, Princeton, NJ, USA; intra-CV, 7.6%; inter-CV, 4.0%) and urine CrossLaps ELISA (Nordic Bioscience Diagnostics, Glostrup, Denmark; intra-CV, ≤3.9%; inter-CV, ≤6.9%). Urinary hydroxyproline (uHyp) was measured using the capillary electrophoresis method (intra-CV, 3.0%; inter-CV, 3.9%) at MBC in 14 OI patients (type I, n = 7; type III, n = 4; type IV, n = 3) and healthy control children. Values of uNTx, uβCTx, and uHyp were normalized to values of urinary creatinine concentration (nmol BCE/mmol Cr, μg/mmol Cr, and μmol/mmol Cr, respectively). Therefore, the values of uNTx, uβCTx, and uHyp shown in this article are those of uNTx, uβCTx, and uHyp that have already been normalized to values of urinary creatinine concentrations.
Statistics
Statistical analyses were performed using a software program (StatView-J 5.0; SAS Institute, Cary, NC, USA). All values are shown as mean ± standard deviation. Differences between classifi cations of the OI patients and difference between OI patients and healthy control children were evaluated using unpaired t tests. Differences were inferred to be signifi cant at P < 0.05.
Results
Results of biochemical testing in OI patients
Results of biochemical testing in OI patients followed our hospital are shown in Table 2 . Ages did not show any signifi cant difference among Sillence's classifi cations. Serum concentration of calcium, phosphorus, intact parathyroid hormone (PTH), and alkaline phosphatase activity did not show any signifi cant difference among Sillence's classifi cations.
Urinary N-and C-terminal telopeptides of type I collagen
Comparisons of uNTx and uβCTx between OI patients and healthy control children are shown in Fig. 1 . UNTx and uβCTx in OI patients and healthy children showed dependence on age, as previously reported [14, 15] . In OI patients, uNTx and uβCTx tended to be lower than those of the healthy control group. UNTx and uβCTx did not correlate with the classifi cation of OI.
Ratio of uNTx and uβCTx to uHyp UHyp was measured in OI patients and healthy control children to analyze the ratio of uNTx and uβCTx to total collagen degenerative product from the whole body. UHyp showed dependence on age and no correlation to classifi cation of OI as uNTx and uβCTx ( Fig. 2A ) [16] . The ratios of uNTx and uβCTx to uHyp [uNTx/uHyp (nmol BCE/μmol) and uβCTx/uHyp (μg/μmol), respectively] in healthy control children did not show any age dependency (Fig. 2B ). In patients with OI, uNTx/uHyp and uβCTx/uHyp were signifi cantly lower than in healthy control children (uNTx/ uHyp, 4.9 ± 1.1 and 7.6 ± 3.2, respectively; P = 0.005; uβCTx/ uHyp, 7.8 ± 2.5 and 13.7 ± 5.8, respectively; P = 0.001). No signifi cant difference was found between classifi cations of OI, uβCTx/uHyp. In contrast, uNTx/uHyp in type III OI was signifi cantly lower than in either type I or type IV OI (Fig. 2C) .
Ratio of uNTx to uβCTx
Next, ratios of uNTx to uβCTx (uNTx/uβCTx; nmol BCE/ μg) in healthy control children were analyzed. Results indicated no dependence of uNTx/uβCTx on age (Fig. 3A) . Next, this ratio was analyzed in OI patients. In type I OI, uNTx/uβCTx represented equivalent value with type IV OI. In type III OI, uNTx/uβCTx was signifi cantly lower than that of either type I or type IV OI patients (type I, 0.78 ± 0.22; type III, 0.44 ± 0.07; type IV, 0.79 ± 0.26; Fig. 3B ). Among the patients before the initial pamidronate infusion (type I, 3; type III, 1), uNTx/uβCTx in type III was lower than in type I (type I, 0.81 ± 0.26; type III, 0.50).
Discussion
In this study, pyridinoline cross-link formation was found to be more disrupted in patients with osteogenesis imperfecta (OI) than in healthy control children. uNTX and uβCTx might be good markers for determining the clinical severity of OI.
Bone resorptive markers such as pyridinoline, deoxypyridinoline, NTx, and CTx are used for monitoring bone metabolism in various situations such as growth in children and for monitoring endocrinological disorders including postmenopausal osteoporosis and hyperthyroidism [17] [18] [19] [20] . These markers, NTx and CTx, are bone-specifi c telopeptides that derive from N-and C-termini of type I collagen (Col I) molecules and contain pyridinoline cross-links [20, 21] . The latter, CTx, is isomerized from the α-to the β-form by a nonenzymic chemical reaction [15, 23] , and bone shows this isomerization most abundantly [24] . Ratios of isomerization are stable from birth to puberty [15] . uNTx and uβCTx were used in this study to assess not only the amount of pyridinoline cross-link but also the balance of pyridinoline cross-link formation at the N-and C-terminus in the type I collagen molecule in patients with OI and healthy control children because of their specifi city to bone. Hyp refl ects the degeneration of whole collagen in the human body and has been used recently for analyzing abnormalities of collagen metabolism [25, 26] . To compare the balance of uNTx and uβCTx excluding their age dependency and to correct differences of body composition between healthy controls and patients with OI or among Sillence's classifi cation, uNTx/uHyp and uβCTx/uHyp were analyzed.
Although it remains controversial whether the number of pyridinoline cross-links in OI patients differs from healthy children [8, 9, 26] , our results show that pyridinoline crosslink formation at N-and C-termini is lower in patients with OI than in healthy children. This difference might be partly attributable to the difference in the age of analyzed OI patients. Our OI patients include infants under 2 years old, in contrast to recent reports that analyzed patients 2 years old and older or adults. Bone turnover decreases as age increases, except in the adolescent period [17] . Therefore, the difference in pyridinoline cross-link formation between OI patients and healthy children might become obscure as age increases. These results indicate that differences of bone fragility between OI patients and healthy children might be partly attributable to differences of the total amount of pyridinoline cross-links.
Our results also show that pyridinoline cross-link formation at N-and C-termini varies according to the OI classification. The ratio of uβCTx to urinary Hyp (uβCTx/uHyp) shows no signifi cant differences among classifi cations of OI. The ratio of uNTx to uHyp (uNTx/uHyp) in type III OI, which is the most severe form in OI patients except type II, shows a lower value than type I and type IV OI, which denote mild OI and mild to severe OI, respectively. Pyridinoline cross-links bind collagen molecules to each other and strengthen Col I fi bers. These results indicate that the various degrees of bone fragility in patients with OI might be attributable in part to the balance of pyridinoline crosslink formation at N and C termini. Values of uNTx/uβCTx in normal children are between type III OI and type I or IV OI. This fi nding also supports that balance of pyridinoline cross-link formation at N and C terminus of Col I molecule is abnormal in patients with OI and might indicate that an abnormal balance of pyridinoline cross-link formation at the N-and C-termini of Col I fi bers exists in some healthy control children, although its abnormality or its effect to bone fragility is masked by the abundant amount of pyridinoline cross-links.
In conclusion, our results show that pyridinoline crosslink formation is impaired in OI patients and that pyridinoline cross-links formation at the N-and C-termini between Col I molecules varies according to severity in patients with OI. Although additional work, for example, that related to glycosylation of collagen [27] , remains to be done, uNTx and uβCTx might be good markers for determining the severity of OI.
